Jan 052018
 
Share

Denali Therapeutics announced positive results from its first-in-human LRRK2 inhibitor clinical trial. The experimental treatment is safe, and it lowers LRRK2 protein activity in humans’ body cells. This is a meaningful milestone in …

View Full Article

Author:  Maggie McGuire Kuhl ,  Publication:  FOX FEED blog  Date: 12-21-2017